Idactamab

Names

[ Name ]:
Idactamab

Biological Activity

[Description]:

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5)[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[Target]

ASCT2 (SLC1A5)[1]

[In Vitro]

Idactamab 对不同血红素癌症细胞系具有抑制作用，IC50 为 0.05-65 ng/mL[1]。 ASCT2 (SLC1A5) 是一种多通道、Na+ 依赖的中性氨基酸转运体，介导肿瘤生长和进展所需氨基酸的摄取[1]。

[In Vivo]

Idactamab 能够提高 3 种播散性急性髓性白血病 (AML) 细胞系模型：TF1α (ASCT2 高表达)、MOLM-13 (ASCT2 低表达) 和 M.V.411 (ASCT2 高表达) 的生存率，对应的最低抑制浓度分别为 0.05 mg/kg，0.1 mg/kg，和 0.1 mg/kg[2]。

[References]

[1]. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.

[2]. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.